Accessibility Menu
OncoVista Innovative Therapies logo

OncoVista Innovative Therapies(OTC) OVIT

Current Price$0.00
Market Cap$2.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-100%
5 Year-100%
1 Year+0%
1 Month+0%
OncoVista Innovative Therapies last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-02
OncoVista Innovative Therapies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-02-13
1 month+0%USD 0.002026-02-13
3 month+0%USD 0.002026-02-13
Year to date-75%USD 0.002025-12-30
1 year+0%USD 0.002025-05-07
3 year-50%USD 0.002023-06-30
5 year-99.86%USD 0.072021-07-01
Since inception-100%USD 2.502007-11-14

OncoVista Innovative Therapies Financials at a Glance

Market Cap

$2.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$3.27M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

42.98 (High)

Price

$0.00

Volume

10,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

OVIT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About OncoVista Innovative Therapies

OncoVista Innovative Therapies, Inc. is a biotechnology company focused on developing targeted anticancer therapies utilizing tumor-associated biomarkers. Founded in 2004 and based in San Antonio, Texas, the company aims to innovate in the healthcare sector.

Products and Services
  • Development of targeted anticancer therapies
  • Utilization of tumor-associated biomarkers for treatment
  • Research and development in the biotechnology field
Growth Outlook
  • Potential for growth in the oncology market, valued at over $200 billion
  • Focus on innovative therapies aligns with industry trends
  • Strategic partnerships could enhance research capabilities
Financial Highlights
  • Recent quarterly net income of -$326,098
  • Trailing twelve months (TTM) revenue of $0
  • Cash and cash equivalents of $61,270 as of September 30, 2015
OncoVista Innovative Therapies, Inc. operates in a highly competitive biotechnology sector, with a focus on cancer treatment. The company has not reported any revenue in recent quarters, indicating a need for further development and potential investment in research. The recent net income figures reflect ongoing operational challenges, yet the company maintains a strategic position in a growing market. With a focus on innovative therapies and potential partnerships, OncoVista may present opportunities for future growth in the oncology landscape.
AI Generated • Jul 24, 2026

Industry

Biotechnology

Headquarters

San Antonio, TX 78245, US

OVIT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

57.94%

Return on Capital

N/A

Return on Assets

-20332.37%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

23.56M

Volume

10.00K

Avg. Volume

161.29

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$3.40M

EBITDA

-$3.26M

Operating Cash Flow

-$264.36K

Capital Expenditure

$0.00

Free Cash Flow

-$264.36K

Cash & ST Invst.

$61.27K

Total Debt

$479.30K

OncoVista Innovative Therapies Performance Analysis

OncoVista Innovative Therapies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42014-12-31N/A
Q12015-03-31N/A
Q22015-06-30N/A
Q32015-09-30N/A
OncoVista Innovative Therapies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42014-12-31-826.0%
Q12015-03-3186.2%
Q22015-06-30-400.0%
Q32015-09-3080.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2015YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$2.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.20K

N/A

Employees

2

N/A

Net Income

-$326.10K

-243.8%

EBITDA

-$317.40K

-238.3%

Quarterly Fundamentals

Name
Q3 2015YOY CHG

Total Cash

$61.27K

-19.0%

Total Debt

$479.30K

+134.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$479.30K

+134.6%

Return on Assets

-203.32%

N/A

Return on Invested Capital

51.29%

N/A

Free Cash Flow

-$26.80K

+66.6%

Operating Cash Flow

-$26.80K

+66.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PAOGPAO Group, Inc.
$0.00-50.00%
LPTILongport, Inc.
$0.00+0.00%
RGMPRegnum Corp.
$0.00+0.00%
COTQFCotinga Pharmaceuticals Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.23+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.22-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$62.79-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$45.62+0.02%

Questions About OVIT

What is the current price of OncoVista Innovative Therapies?

OncoVista Innovative Therapies is trading at $0.00 per share.

What is the 52-week range for OncoVista Innovative Therapies?

Over the past 52 weeks, OncoVista Innovative Therapies has traded between $0.00 and $0.00.

How much debt does OncoVista Innovative Therapies have?

OncoVista Innovative Therapies total debt is unavailable.

How much cash does OncoVista Innovative Therapies have on hand?

OncoVista Innovative Therapies does not have cash on hand data available.

What is OncoVista Innovative Therapies’s dividend yield?

OncoVista Innovative Therapies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.